Post Marketing Surveillance To Observe Safety And Efficacy Of Xyntha® In Subjects With Hemophilia A

• Status: Completed
• Trial end date: 2014-08-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is to describe the safety and efficacy of Xyntha® during the usual care setting.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Factor VIII

Criteria

Inclusion Criteria:

• Patients or legally authorized representatives of pediatric patients agree to provide written informed consent form (data privacy statement).

• Pediatric and adult patients who have been treated with Xyntha for Hemophilia A from first approved date by KFDA, or who are planned to be newly prescribed Xyntha.

Exclusion Criteria:

• Patients with a known history of hypersensitivity to original or reformulated Xyntha or any component of the product.

• Patients with a known history of hypersensitivity to hamster protein.

• Patients participating in an interventional trial of any investigational drug or device.